We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$241M
AUM Growth
-$49.5M
Cap. Flow
-$56.8M
Cap. Flow %
-23.61%
Top 10 Hldgs %
81.6%
Holding
34
New
–
Increased
3
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$5.15M
2
ARGX icon
argenx
ARGX
+$1.37M
3
ROIV icon
Roivant Sciences
ROIV
+$1.01M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.9M
2
MRNA icon
Moderna
MRNA
+$10.3M
3
IMGN
Immunogen Inc
IMGN
+$10.3M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$9.63M
5
APLS
Apellis Pharmaceuticals
APLS
+$9.38M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
1
Novo Nordisk
NVO
$216B
$62M 25.78%
681,812
– –
MRK icon
2
Merck
MRK
$324B
$33.9M 14.09%
329,200
– –
ARGX icon
3
argenx
ARGX
$57.4B
$24.2M 10.06%
49,238
+2,800
+6% +$1.37M
LLY icon
4
Eli Lilly
LLY
$1.07T
$14.1M 5.85%
26,193
+10,000
+62% +$5.15M
ABBV icon
5
AbbVie
ABBV
$458B
$13.5M 5.63%
90,821
– –
AZN icon
6
AstraZeneca
AZN
$263B
$12.9M 5.37%
95,376
– –
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$10.9M 4.51%
51,175
– –
ROIV icon
8
Roivant Sciences
ROIV
$25.2B
$10.7M 4.44%
914,023
+89,660
+11% +$1.01M
ETNB
9
DELISTED
89bio
ETNB
$7.19M 2.99%
465,465
– –
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.5B
$6.94M 2.89%
78,465
– –
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.66B
$6.93M 2.88%
57,162
-20,000
-26% -$2.26M
VRTX icon
12
Vertex Pharmaceuticals
VRTX
$121B
$6.37M 2.65%
18,314
– –
AXSM icon
13
Axsome Therapeutics
AXSM
$12.4B
$6.14M 2.55%
87,848
– –
NBIX icon
14
Neurocrine Biosciences
NBIX
$17.7B
$5.06M 2.1%
45,000
– –
VKTX icon
15
Viking Therapeutics
VKTX
$4.04B
$4.25M 1.77%
383,580
– –
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$36.3B
$2.83M 1.18%
15,971
– –
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.17M 0.9%
41,600
– –
PCVX icon
18
Vaxcyte
PCVX
$7.89B
$1.97M 0.82%
38,555
– –
PTGX icon
19
Protagonist Therapeutics
PTGX
$8.75B
$1.87M 0.78%
112,340
– –
PLRX icon
20
Pliant Therapeutics
PLRX
$67.5M
$1.73M 0.72%
100,000
– –
CRL icon
21
Charles River Laboratories
CRL
$10.9B
$1.35M 0.56%
6,905
– –
TMO icon
22
Thermo Fisher Scientific
TMO
$211B
$1.07M 0.44%
2,109
-2,979
-59% -$1.59M
WAT icon
23
Waters Corp
WAT
$36.8B
$780K 0.32%
2,845
– –
TYRA icon
24
Tyra Biosciences
TYRA
$1.82B
$623K 0.26%
45,253
– –
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$615K 0.26%
41,261
-128,016
-76% -$1.7M
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Artia Global Partners held 34 positions worth $241M, down 17% from $290M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artia Global Partners withdrew a net $56.8M in Q3 2023, closing 7 positions and reducing 3 holdings. Its most notable exit was Biogen, an estimated $14.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Artia Global Partners added an estimated $5.15M to Eli Lilly.

  • Artia Global Partners added most to Eli Lilly in Q3 2023, an estimated $5.15M increase.
  • Artia Global Partners's biggest Q3 2023 reduction was Sarepta Therapeutics, cutting an estimated $2.26M.
  • Artia Global Partners fully exited Biogen in Q3 2023, selling an estimated $14.9M.
  • Artia Global Partners's ten largest holdings make up 82% of its $241M portfolio in Q3 2023.
  • Artia Global Partners opened 0 new positions and closed 7 in Q3 2023.
  • Artia Global Partners's portfolio value fell 17% quarter-over-quarter to $241M.

Based on Artia Global Partners's 13F filing for Q3 2023, filed 14 Nov 2023.